Select Page ::

Kessler Foundation study advances knowledge of role of brain pathology and cognitive fatigue in multiple sclerosis – EurekAlert

Posted on October 3, 2022 by Danzig

image:This study was conducted using the latest neuroimaging techniques at the Ortenzio Center, which is dedicated solely to rehabilitation research, view more

Credit: Kessler Foundation

East Hanover, NJ. September 30, 2022. Using advanced diffusion neuroimaging technology, Kessler Foundation researchers investigated the relationship between the rate of cognitive fatigue to microstructural changes in the brain in persons with multiple sclerosis. Their findings help fill a gap in the current understanding of how brain pathology influences the development of fatigue over time.

Their findings were reported in Frontiers in Neurology on July 04, 2022, in the open access article Associations of White Matter and Basal Ganglia Microstructure to Cognitive Fatigue Rate in Multiple Sclerosis, (doi: 10.3389/fneur.2022.911012). The authors are Cristina Almeida Flores Romn, PhD, Glenn Wylie, DPhil, John DeLuca, PhD, and Bing Yao, PhD, and of Kessler Foundation.

The study was conducted at the Rocco Ortenzio Neuroimaging Center at Kessler Foundation, which is dedicated solely to rehabilitation research. Participants were 62 individuals with relapsing-remitting MS. All completed questionnaires measuring depression, state and trait anxiety, and trait fatigue. While in the scanner, participants underwent a cognitively fatiguing task. In addition to measuring rate of cognitive fatigue, researchers measured whole brain lesion volume and performance during the fatigue-inducing task.

We found that the cognitive rate related to white matter tracts, many with associations with the basal ganglia or what we have proposed as the fatigue network, said lead author Dr. Romn, National MS Society postdoctoral fellow at Kessler Foundation. These findings bring us closer to understanding how brain pathology impacts the experience in the moment. This is fundamental to developing effective interventions for managing the disabling fatigue of MS and other neurological conditions.

Funding: Kessler Foundation, National Multiple Sclerosis Society (RG-1701-26930)

Learn more about ongoing studies at Kessler Foundation at Join Our Research Studies | Kessler Foundation

About Kessler Foundation

Kessler Foundation, a major nonprofit organization in the field of disability, is a global leader in rehabilitation research that improves cognition, mobility, and long-term outcomes, including employment, for people with neurological disabilities caused by diseases and injuries of the brain and spinal cord. Kessler Foundation leads the nation in funding innovative programs that expand opportunities for employment for people with disabilities. Learn more by visiting http://www.KesslerFoundation.org

Stay Connected

Twitter |http://Twitter.com/KesslerFdnFacebook |http://Facebook.com/KesslerFoundationYouTube |http://Youtube.com/user/KesslerFoundationInstagram |http://Instagram.com/kesslerfdn

iTunes & SoundCloud |http://Soundcloud.com/kesslerfoundation

To interview an expert, contact:

Deborah Hauss, DHauss@kesslerfoundation.org

Carolann Murphy, CMurphy@KesslerFoundation.org

Frontiers in Neurology

Imaging analysis

People

Associations of White Matter and Basal Ganglia Microstructure to Cognitive Fatigue Rate in Multiple Sclerosis

4-Jul-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

DWP: You could be entitled to 156 per week if you have any of these 70 neurological conditions – Cambridgeshire Live

Posted on October 3, 2022 by Danzig

The Department of Work and Pensions offers extra support to people with a range of neurological conditions. Illnesses such as epilepsy, motor neurone disease and multiple sclerosis are all covered by the Personal Independent Payment (PIP).

According to the DWP nearly 3 million people in the UK are claiming extra support and over 300,000 claim it for a neurological condition. The PIP benefit is available to over 70 conditions and can help families struggling under the cost of living crisis, The Daily Record reports.

You could be entitled to 156 per week if you have any of these 70 neurological conditions. The PIP can be claimed as long as the following applies:

Read more: DWP: Benefits may not rise with the rate of inflation warns treasury

Cerebrovascular disease

Epilepsy

Non epileptic disturbance of consciousness

Movement disorders

Multiple sclerosis

Benign tumours

Hydrocephalus

Headache

Head injury

Spinal cord compression

Degenerative neuronal diseases

Cerebral palsy

Spina bifida

Ataxia

Neuropathy

Peripheral nerve injury

Disease of muscle

Muscular dystrophy

Neurology Scandal Patients ‘Must Get Access To The Truth’ – 4ni.co.uk

Posted on October 3, 2022 by Danzig

Patients misdiagnosed in the Neurology scandal must get access to the truth about what happened to them, Sinn Fin MLA Carl N Chuiln has said.

Speaking after the Belfast Trust appeared before the Neurology APG, the North Belfast MLA said: "It is unacceptable that patients and families impacted by the neurology scandal are still waiting for truth and accountability.

"The Independent Inquiry report is nothing short of damming and has cataloged missed opportunities to address their treatment.

"The RQIA report on governance in outpatients - published in Feb 2020 - made 26 recommendations for improvements in Neurology services, and for many families, they feel that very little progress has been made since then.

"Former patients have had their confidence rocked and the Belfast Trust need to do more to support all those failed by Michael Watt.

"Sinn Fin will continue to support the victims and their families in their campaign for truth and accountability."

Continue reading here:
Neurology Scandal Patients 'Must Get Access To The Truth' - 4ni.co.uk

Research finds that social isolation is directly associated with later dementia – EurekAlert

Posted on June 9, 2022 by Danzig

Social isolation is directly linked with changes in the brain structures associated with memory, making it a clear risk factor for dementia, scientists have found.

Setting out to investigate how social isolation and loneliness were related to later dementia, researchers at the University of Warwick, University of Cambridge and Fudan University used neuroimaging data from more than 30,000 participants in the UK Biobank data set. Socially isolated individuals were found to have lower gray matter volumes of brain regions involved in memory and learning.

The results of the study are published online today (June 8, 2022) in Neurology, the medical journal of the American Academy of Neurology, in a paper entitled Associations of social isolation and loneliness with later dementia by Shen, Rolls, Cheng, Kang, Dong, Xie, Zhao, Sahakian and Feng (doi: 10.1212/WNL.0000000000200583).

Based on data from the UK Biobank, an extremely large longitudinal cohort, the researchers used modelling techniques to investigate the relative associations of social isolation and loneliness with incident all-cause dementia. After adjusting for various risk factors (including socio-economic factors, chronic illness, lifestyle, depression and APOE genotype), socially isolated individuals were shown to have a 26% increased likelihood of developing dementia.

Loneliness was also associated with later dementia, but that association was not significant after adjusting for depression, which explained 75% of the relationship between loneliness and dementia. Therefore, relative to the subjective feeling of loneliness, objective social isolation is an independent risk factor for later dementia. Further subgroup analysis showed that the effect was prominent in those over 60 years old.

Professor Edmund Rolls, neuroscientist from the University of Warwick Department of Computer Science, said: There is a difference between social isolation, which is an objective state of low social connections, and loneliness, which is subjectively perceived social isolation.

Both have risks to health but, using the extensive multi-modal data set from the UK Biobank, and working in a multidisciplinary way linking computational sciences and neuroscience, we have been able to show that it is social isolation, rather than the feeling of loneliness, which is an independent risk factor for later dementia. This means it can be used as a predictor or biomarker for dementia in the UK.

With the growing prevalence of social isolation and loneliness over the past decades, this has been a serious yet underappreciated public health problem. Now, in the shadow of the COVID-19 pandemic there are implications for social relationship interventions and care particularly in the older population.

Professor Jianfeng Feng, from the University of Warwick Department of Computer Science, said: We highlight the importance of an environmental method of reducing risk of dementia in older adults through ensuring that they are not socially isolated. During any future pandemic lockdowns, it is important that individuals, especially older adults, do not experience social isolation.

Professor Barbara J Sahakian, of the University of Cambridge Department of Psychiatry, said: "Now that we know the risk to brain health and dementia of social isolation, it is important that the government and communities take action to ensure that older individuals have communication and interactions with others on a regular basis."

-ends-

Notes to Editors:

The paper is available under embargo, on request via the contact details below.

Media information:

Andrea Cullis

Media relations manager

University of Warwick

MB: 07825 314874

E: a.cullis@warwick.ac.uk

American Academy of Neurology

media@aan.com

Associations of social isolation and loneliness with later dementia

8-Jun-2022

Read the original here:
Research finds that social isolation is directly associated with later dementia - EurekAlert

Precision Surgery Device Market Size to Hit USD 18.99 Billion by 2030 | Rising Demand in Neurological Surgical Procedures & High Investment by Top…

Posted on October 3, 2022 by Danzig

The Brainy Insights

Global precision surgery device market growth would be driven by the increasing incidence of accidents, sports injuries, and other diseases that require surgical intervention. The growing research and development of innovative wound closure devices are gaining traction in the medical industry. The North American region emerged as the largest market for the global precision surgery device market, with a 37.66% share of the market revenue in 2021.

Newark, Sept. 30, 2022 (GLOBE NEWSWIRE) -- As per the report published by The Brainy Insights, the globalprecision surgery device market is expected to grow from USD 5.14 billion in 2021 to USD 18.99 billion by 2030, at a CAGR of 15.63% during the forecast period 2022-2030.

A sedentary lifestyle, lack of exercise, bad eating habits, and a rise in the number of hours spent in front of laptops and smartphone displays have all contributed to an increase in the number of people with acute and chronic diseases. Cardiovascular, respiratory, and orthopedic diseases are becoming more common among the aging population. Precision surgery devices are increasingly used in surgical procedures due to their minimally invasive nature and quicker healing times. The global market is driven during the forecast period by the rising usage of precision surgery equipment and the rising prevalence of disorders.

Request PDF Brochure: https://www.thebrainyinsights.com/enquiry/sample-request/12935

Accidents are also among the leading causes of death worldwide, which will drive the market's growth. Major players have invested capital into research and system development to meet the growing need for precision surgery technologies. Robust technological advancements and developments in precision surgery equipment will boost industry efficiency and competitiveness, fostering the sector's expansion and creating profitable prospects for market participants. However, the high cost of precision surgery devices can hamper the market's growth. Stringent government guidelines and regulations will also challenge the market forecast period. The lack of skilled professionals to operate these devices will also limit the market's growth. Innovations and comprehensive approval mechanisms can help overcome these challenges and provide an impetus to the global precision surgery device market.

Story continues

Competitive Strategy

To enhance their market position in the global precision surgery device market, the key players are now focusing on adopting the strategies such as product innovations, mergers & acquisitions, recent developments, joint ventures, collaborations, and partnerships.

In August 2022, Edwards Lifesciences' Pascal Precision system, its newest treatment for mitral and tricuspid regurgitation patients, received a CE mark. With the regulatory nod, Edwards will be able to launch the surgical device in the European market. According to a statement offered by the company's CEO, the firm is scheduled to receive approval from the FDA before year-end.

Market Growth & Trends

The rise in accidents, sports injuries, and other conditions requiring surgical intervention will fuel the market for precision surgery devices. The medical sector is witnessing an increase in the study, research, and development of novel wound closure devices, which is anticipated to drive product innovations in the market. Precision surgery devices are becoming more widely used in healthcare due to their minimally invasive design and improved post-operative healing. Precision surgery gadgets are less painful than open operations, so the aging population will drive the market for them. Additionally, it lessens discomfort and enables the patient to reduce scarring. The dangers of open surgery, such as harm to internal organs, are minimized. Medical experts can also use precision surgery tools to repair the little anomalies that were previously impossible to fix. Advances in artificial intelligence and machine learning are creating lucrative opportunities in the market. Precision surgery equipment is becoming more widely used due to the use of robotics and the internet of things (IoT) in medicine to increase hospital success or survival rates.

If you have any questions, please feel free to contact our analyst at: https://www.thebrainyinsights.com/enquiry/speak-to-analyst/12935

Key Findings

In 2021, the cardiovascular segment dominated the market with the largest market share of 45% and market revenue of 2.31 billion.

The application segment is divided into orthopedic, neurosurgery, cardiovascular, wound closure, and others. In 2021, the cardiovascular segment dominated the market with the largest market share of 45% and market revenue of 2.31 billion.

The handheld surgical devices segment is expected to grow at the fastest CAGR of 17.15% over the forecast period.

The type segment is divided into handheld surgical devices, electrosurgical devices, and others. Over the forecast period, the handheld surgical devices segment is expected to grow at the fastest CAGR of 17.15%.

In 2021, the hospitals' segment accounted for the largest share of the market, with 53% and a market revenue of 2.72 billion.

The end-user segment is divided into hospitals, specialty clinics, ambulatory settings, long-term care centers, and others. In 2021, the hospitals' segment accounted for the largest share of the market, with 53% and a market revenue of 2.72 billion.

Regional Segment Analysis of the Precision Surgery Device Market

North America (U.S., Canada, Mexico) Europe (Germany, France, U.K., Italy, Spain, Rest of Europe) Asia-Pacific (China, Japan, India, Rest of APAC) South America (Brazil and the Rest of South America) The Middle East and Africa (UAE, South Africa, Rest of MEA)

Among all regions, the North American region emerged as the largest market for the global precision surgery device market, with a market share of around 37.66% and 1.93 billion of the market revenue in 2021. Healthcare is more readily available and more reasonably priced for the populace due to the high per capita income and the established insurance market with favorable reimbursement policies in the region. The growing elderly population also fuels the growing need for surgery. The market for precision surgery devices has benefited from the growing need for reconstructive, plastic, and other procedures to enhance body aesthetics. Furthermore, the rising government spending on healthcare infrastructure will influence the market's growth in the upcoming years.

Interested in Procuring This Report? Visit Here: https://www.thebrainyinsights.com/enquiry/speak-to-analyst/12935

Key players operating in the global precision surgery device market are:

Alcon Aspen Surgical B. Braun SE Baxter Boston Scientific Johnson & Johnson Medtronic PLC Siemens Healthcare GmbH Stryker Corporation Zimmer Biomet

This study forecasts global, regional, and country revenue from 2019 to 2030. The Brainy Insights has segmented the global precision surgery device market based on the below-mentioned segments:

Global Precision Surgery Device Market by Application:

Orthopedic Neurosurgery Cardiovascular Wound Closure Others

Global Precision Surgery Device Market by Type:

Handheld Surgical Devices Electrosurgical Devices Others

Global Precision Surgery Device Market by End User:

Hospitals Specialty Clinics Ambulatory Settings Long-Term Care Centers Others

About the report:

The global precision surgery device market is analyzed based on value (USD Billion). All the segments have been analyzed on a worldwide, regional, and country basis. The study includes the analysis of more than 30 countries for each part. The report offers an in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining critical insight into the market. The study includes porter's five forces model, attractiveness analysis, raw material analysis, supply, and demand analysis, competitor position grid analysis, distribution, and marketing channels analysis.

About The Brainy Insights:

The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients' objectives of high-quality output within a short span of time. We provide both customized (clients' specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients' requirement whether they are looking to expand or planning to launch a new product in the global market.

Avinash DHead of Business DevelopmentPhone: +1-315-215-1633Email: sales@thebrainyinsights.comWeb: http://www.thebrainyinsights.com

Here is the original post:
Precision Surgery Device Market Size to Hit USD 18.99 Billion by 2030 | Rising Demand in Neurological Surgical Procedures & High Investment by Top...

Gene Therapy on Neurological Diseases Market Size, Share, Segmentation, And Forecast 2030 – PharmiWeb.com

Posted on October 3, 2022 by Danzig

Pune, Maharashtra, September 29 2022 (Wiredrelease) Market.Biz :Discover the game-changing elements and trends that are impacting Gene Therapy in Neurological Diseases Market With Market.biz, you can navigate the complexities of Gene Therapy in the Neurological Diseases industry.

Global Gene Therapy on Neurological Diseases Market Analysis:

The Gene Therapy on Neurological Diseases reports overview is a compilation of the most recent trends and figures that reveal a broad analysis of the market drivers, revenue share, segmentation, and geographical markets. It investigates a wide range of topics, including regional market scope, product-market various applications, market size according to a specific product, sales and revenue by region, production cost analysis, supply chain, market influencing factors analysis, market size estimates, and more. This market analysis includes an overview of Gene Therapy in the Neurological Diseases industry, a look at the target market, a competition analysis, business projections, and regulations. The following are the main points discussed:

Description and forecast for the industry:

First and foremost, this is where youll discover information about the present situation of the Gene Therapy in Neurological Diseases business and where its heading. This section includes industry indicators such as size, trends, life cycle, and predicted growth. This report includes statistics to back up your company concept. The worldwide Gene Therapy on Neurological Diseases market is divided into North America; Europe; Asia Pacific; Latin America; The Middle East & Africa.

Request a PDF Sample: https://market.biz/report/global-gene-therapy-on-neurological-diseases-market-gm/#requestforsample

Market Segmentation Analysis

This studys target market segment contains the following:

Demographics such as age, income, and geography are included in the user persona and attributes. It informs you of their hobbies and purchasing habits, as well as the greatest position to suit their demands.

Market size: What is the potential size of the Gene Therapy on Neurological Diseases market for your company? It reveals the consumption in the Gene Therapy on Neurological Diseases business according on Type and application. With respect to Type, segmentation is carried out under Viral Gene Therapy; Non-viral Gene Therapy. And concerning the applications, segmentation Hospital; Clinic

Analysis of competitors: Learn about Gene Therapy on Neurological Diseases competitors. The study not only informs you about your competition, but it also identifies their flaws. Is there a client base that is underserved? What do you have to offer that other companies dont? The competitive analysis includes the following elements:

Direct competitors include: What other businesses provide comparable goods and services? Which firms are your genuine rivals? All of these issues are addressed in the paper. This section also provides Biogen; Novartis; Sarepta Therapeutics analysis.

Indirect competitors: Similarly, this report informs you that you are not competing with Gene Therapy on Neurological Diseases firms, but rather report Cat companies.

What are the strengths and shortcomings of your competition? Where are they falling short? Learn how to discover opportunities to flourish when others are failing.

What are the possible drawbacks of joining the Gene Therapy on Neurological Diseases market? What is the entrance fee? Is it unreasonably expensive or simple to enter? This is where you look at your flaws.

The opportunity window: Finally, do you plan to enter the Gene Therapy on Neurological Diseases sector using time-sensitive technology? Is it necessary to enter early to capitalise on an emerging market? As a result, the study addresses all of these concerns.

So, what will the reality be in 2023? Inquire, learn, and get https://market.biz/report/global-gene-therapy-on-neurological-diseases-market-gm/#inquiry

Projections: Similarly, We provided deliberate forecasting rather than hockey-stick forecasting. Market share We have also provided consumer consumption behaviour. Only you will comprehend how much of the Gene Therapy on Neurological Diseases sector you have a chance to capture once you know how much your prospective clients can pay. And this is where we came up with actual statistics and data. Bottom-up predictions will show how your marketing and sales activities will allow you to capture a specific share of the market.

Pricing and gross margin: We also design a pricing structure. The difference between your Gene Therapy on Neurological Diseases expenditures and the Gene Therapy on Neurological Diseases sales price is your gross margin. These positive estimates might not only serve as a guide, but also as an incentive.

Regulations: Is there any special governmental rules or limits on the Global Gene Therapy on Neurological Diseases Market? If thats the case, it brought them up here and spoke about how to comply with them.

Success Factors: Above all, what criteria distinguish success from failure? We identified key parameters based on Gene Therapy on Neurological Diseases categories, which include pricing, value, availability, features, financing, upgrades or return policies, and customer service.

Most importantly, this market study can assist you in identifying market blind spots.

Buy Report: https://market.biz/checkout/?reportId=839259&type=Single%20User

Thank you for reading it all the way to this point.

Contact number: +1 (857)4450045, +91 9130855334.Email: inquiry@market.biz

Immunity Booster Supplement Market Will Help To Minimize The Risk Of Virus Infection: https://www.pharmiweb.com/press-release/2022-09-26/immunity-booster-supplement-market-will-help-to-minimize-the-risk-of-virus-infection

High-end Fish Oil Market Leading Industries, and Upcoming Opportunity Analysis To 2030: https://www.pharmiweb.com/press-release/2022-09-28/high-end-fish-oil-market-leading-industries-and-upcoming-opportunity-analysis-to-2030

Therapeutic Proteins for Cardiovascular Disorders Treatment Market Leading Vendors, And Forecast Assessment To 2030: https://www.pharmiweb.com/press-release/2022-09-28/therapeutic-proteins-for-cardiovascular-disorders-treatment-market-leading-vendors-and-forecast-ass

Veterinary Infectious Diseases Therapeutics Market Will Grow With Highest CAGR During Forecast Period Till 2030: https://www.pharmiweb.com/press-release/2022-09-28/veterinary-infectious-diseases-therapeutics-market-will-grow-with-highest-cagr-during-forecast-perio

This content has been published by Market.Biz company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.

Originally posted here:
Gene Therapy on Neurological Diseases Market Size, Share, Segmentation, And Forecast 2030 - PharmiWeb.com

Dr. Terrie Inder, a leading neonatologist and child neurologist, named to new position of chair of Center of Neonatal Research at CHOC – PR Newswire

Posted on June 9, 2022 by Danzig

ORANGE, Calif., June 8, 2022 /PRNewswire/ -- Children's Hospital of Orange County (CHOC) has recruited dual-boarded neonatologist and child neurologist Dr. Terrie Inder, internationally known for her clinical and scholarly innovation, leadership, and mentoring, to the newly created position of chair of neonatal research.

Currently chair of the department of pediatric newborn medicine at Brigham and Women's Hospital, a major teaching hospital at Harvard Medical School in Boston, Dr. Inder will lead the development of the Center of Neonatal Research at CHOC starting Sept. 1, 2022.

Her appointment highlights CHOC's mission to advance research and clinical outcomes for children and families, said Dr.Vijay Dhar, division chief of neonatology for CHOC Specialists.

"She joins a stellar team of clinicians," Dr. Dhar said. "Together, we will make CHOC the leading destination for neonatal- perinatal care, research and training."

Dr. Inder, an expert in the development of the newborn brain, aims to build on her track record of clinical and academic excellence at CHOC, where she'll lead efforts to advance scientific studies and improve clinical outcomes in neonatal- perinatal medicine.

"CHOC has a very dedicated group of clinicians who are hungry to make a difference, and I hope, with true humility and privilege, to be able to help them a little bit," said Dr. Inder, adding that she found CHOC's leaders to be "phenomenally grounded, aspirational and hard-working."

Will lead 80 neonatologists

The Center of Neonatal Research at CHOC will advance scientific studies and improve clinical outcomes in the field of neonatal-perinatal medicine. In collaboration with UC Irvine, Dr. Inder will coordinate participation at conferences, develop doctoral and post-doctoral programs, recruit research scientists, and provide research opportunities for residents and fellows.

She also will mentor a staff of 80 neonatologists based at CHOC, UCI and a network of neonatal intensive care units (NICUs) and birthing centers totaling more than 300 NICU beds and nearly 50,000 births a year.

"I am thrilled that Dr. Inder will be joining us," said Dr. Terry Sanger, CHOC's chief scientific officer. "Her research has been foundational to the understanding of early brain development and disorders of neonates, including the origins of cerebral palsy. She will be a tremendous contributor to children's health in Southern California, and I am excited to think that the resources of CHOC, UCI and Orange County will be able to support and grow her groundbreaking research."

A record of firsts

A native of New Zealand, Dr. Inder started practicing medicine in the U.S. in 2005 after being recruited by St. Louis Children's Hospital, the pediatric teaching hospital for Washington University School of Medicine in St. Louis, Mo.

There, she founded the Washington University Neonatal Development Research team, which has grown to 55 investigators, and succeeded in securing National Institutes of Health funding to establish the Intellectual and Developmental Disabilities Research Center.

Dr. Inder joined Brigham and Women's Hospital in 2013 as its first chair of pediatric newborn medicine. There, she assisted with rebuilding a new clinical facility with a novel design system optimizing differing models of care, established a neonatal transport program and built a consolidated network, and established more than 50 clinical care pathways and created programs in fetal care and specialized clinical care for neonatal neurocritical care.

At Brigham and Women's, Dr. Inder also increased research funding by tenfold, grew her department's research faculty, and opened a state-of-the-art NICU with single-family rooms and a first-of-its-kind, dedicated magnetic resonance imaging (MRI) system that expanded neurocritical care for babies.

Her department at Brigham and Women's now educates more than 200 trainees in pediatric and neonatal medicine with a commitment to national and international teaching.

Moving up

While practicing in Australia between 2001 and 2005, Dr. Inder also became known for innovation. She founded an MRI facility at the Murdoch Children's Research Institute at Royal Women's Hospital in Melbourne. The novel imaging center required cooperation across multiple departments, research institutes and with the regional and state government.

Recruited by several leading pediatric healthcare systems during her time in Boston, Dr. Inder said she decided to join CHOC because of its people and promise of significant growth in its clinical, research and educational missions.

"I think with the investments being made now, CHOC is on a steady upward trajectory," Dr. Inder said.

Impacting care

With more than 200 peer-reviewed articles published, Dr. Inder's primary research is targeted at understanding the timing, mechanisms and impact of cerebral injury and altered cerebral development in infants at high risk for adverse neurodevelopmental outcome, including the prematurely born infant, the sick term-born infant, and the infant with congenital heart disease.

"All of my research efforts are designed to be immediately translatable to impact care," Dr. Inder said.

One of her many side projects includes working as an editor on the seventh-edition of a landmark work in her field, "Volpe's Neurology of the Newborn," written by Dr. Joseph Volpe, a mentor.

Outside of work, Dr. Inder, who has three adult children, enjoys gardening and spending time her mini-Goldendoodle, Oscar.

About CHOC:

CHOC, a pediatric healthcare system based in Orange County, California, is committed to being a leading destination for children'shealth by providing exceptional and innovative care. Our growing community includes two state-of-the-art hospitals in Orange and Mission Viejo and a regional network of primary and specialty care clinics serving children and families in four counties. CHOC offers several clinical programs of excellence providing the highest levels of care for the most serious pediatric illnesses and injuries, both physical and mental. Our research and innovation institutes are focused on translating real patient needs into real-world treatments so every child can live the healthiest and happiest life possible. To learn more, visit http://www.choc.org.

MEDIA CONTACT: [emailprotected]

SOURCE CHOC

Follow this link:
Dr. Terrie Inder, a leading neonatologist and child neurologist, named to new position of chair of Center of Neonatal Research at CHOC - PR Newswire

Spherix Global Insights Announces Fielding of New Research Geared Towards Fellows and Residents in Immunology, Neurology, Nephrology, and…

Posted on June 9, 2022 by Danzig

The project is designed to explore to what degree the next generation of specialists are prepared to enter clinical practice and what baseline opinions will they be bringing as they move from a training environment into real world patient management

EXTON, Pa., June 7, 2022 /PRNewswire/ -- Fellows will be the next generation of practitioners. Most academic institutions have closed-door policies for industry, leaving a large gap in understanding how these new doctors have been educated on certain disease states with the gap even larger following two years of limited engagement due to COVID-19.

Spherix Global Insights, an independent market intelligence firm, is launching a new Special Topix research service in order to better grasp this segment and provide pharmaceutical stakeholders with what they need to know about future prescribers in their markets.

The Special Topix: Fellows and Residents (US) service is based on an online survey of soon-to-be practicing physicians in advanced training (fellowship and/or residency programs) for dermatology, gastroenterology, nephrology, neurology, ophthalmology, and rheumatology. Their opinions, practices, and attitudes are compared to two cohorts: specialists in practice from one to five years and those in practice for more than ten years.

Each report will include an overview of the various US training programs within that specialty, as well as an understanding of how the fellows (for gastroenterology, nephrology, and rheumatology in particular) and recently graduated residents (for dermatology, neurology, and ophthalmology in particular) have been trained, perceptions of commercial and pipeline products, expected challenges in the first years of practice, and ways in which biopharma can engage and optimize relationships.

With the next crop of specialty physicians about to enter clinical practice, Spherix's Special Topix service will offer clients a deep dive into this group's mindset as attitudes and perceptions change with the times.

Unlike other firms offering syndicated reports, Spherix derives actionable insights from its frequent, commercially-focused, primary market research which is highly customized to each client's unique needs. Possessing unrivalled content expertise and collaborating with a network of highly engaged specialists are essential elements distinguishing Spherix in the business analytics and intelligence space.

About Spherix Global Insights

Spherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select dermatology, gastroenterology, nephrology, neurology, ophthalmology, and rheumatology markets.

All company, brand or product names in this document are trademarks of their respective holders.

For more information contact:Paul Zimmerman, Vice President of InsightsEmail:[emailprotected]www.spherixglobalinsights.com

SOURCE Spherix Global Insights

Go here to read the rest:
Spherix Global Insights Announces Fielding of New Research Geared Towards Fellows and Residents in Immunology, Neurology, Nephrology, and...

Cancer Patient Develops A Rare Neurological Condition That Replaced His Accent With Irish-sounding Voice – Revyuh

Posted on February 19, 2023 by Danzig

Cancer Patient Develops A Rare Neurological Condition That Replaced His Accent With Irish-sounding Voice Revyuh

View original post here:
Cancer Patient Develops A Rare Neurological Condition That Replaced His Accent With Irish-sounding Voice - Revyuh

Neurologists Near Me in Pompano Beach, FL | Healthgrades

Posted on March 23, 2023 by Danzig

A neurologist specializes in caring for people with diseases and conditions of the brain and nervous system, including the spinal cord, nerves, muscles, and related blood vessels. Neurologists diagnose and treat many diseases, including stroke, Alzheimers disease, headaches,seizures, and brain and spinal cord injuries. Neurologists are also experts in preventing neurological disease and in reducing neurological disability.

A neurologist typically:

Evaluates a patients medical history and educates the patient about brain and nervous system health and disease prevention

Performs physical exams that include evaluating blood pressure, vital signs, and the health of the brain and nervous system

Orders and interprets laboratory and imaging tests and prescribes medications

Diagnoses and treats acute and chronic diseases and conditions that affect the brain and nervous system including multiple sclerosis, Parkinsons disease, andmeningitis

Screens, treats and monitors conditions that increase the risk of serious brain and nervous system conditions, such as ahead injurythat can lead to long-term memory loss and headaches

Performs certain invasive procedures such as nervous system biopsies

Provides direct care for brain and nervous system conditions in the office and in the hospital

Works closely with your primary care doctor and other specialists and members of your healthcare team to provide optimal care

Neurologists may also be known by the following names: brain doctor, brain specialist, and nerve doctor.

There are 108 specialists practicing Neurology in Pompano Beach, FL with an overall average rating of 3.7 stars. There are 41 hospitals near Pompano Beach, FL with affiliated Neurology specialists, including Boca Raton Regional Hospital, Holy Cross Hospital and Broward Health North.

Read more from the original source:
Neurologists Near Me in Pompano Beach, FL | Healthgrades

ECP Pharma’s Path Forward Clearer After FDA’s Response To Pre-IND Submission On Its Neurological, CNS Diseases Drug Products – Business Wire

Posted on June 9, 2022 by Danzig

MIAMI--(BUSINESS WIRE)--ECP Pharma has received a favorable, positive written response from the FDA regarding its Pre-IND submission of novel drugs for targeted indications with no clinically proven treatment options using underutilized APIs (Active Pharmaceutical Ingredients).

The FDA provided a clear order of when clinical studies should be conducted by ECP Pharma, which increases the likelihood of successful sequential program development. The battery of nonclinical studies will help to inform the clinical program, which will now follow an outline from the FDA on the requirements needed to commence with its clinical trials. One initial takeaway is that the FDA is supportive of the development of this combination drug therapy program for Neurological and CNS diseases.

"The Pre-IND meeting notes are a wonderful indicator that ECP Pharma is on the right track, says Dr. Michael Hoffer, ECP Pharmas Chief Medical Officer and a Professor of Otolaryngology and Neurological Surgery at the University of Miami. The FDAs feedback provides a clear path forward which will alleviate future headaches with the inclusion of nonclinical feedback to help avoid a Clinical Hold when the IND is submitted. We expect to be on schedule to start first in human trials after our IND submission.

According to Dr. Hoffer, ECP Pharmas focus and areas of research target the field of neuroscience and neurology to identify target indications to develop a robust drug product development pipeline. Its drug discovery process and business development analytics are backed by world-class experts in the fields of drug research, regulatory compliance, and business management. The companys unique collaboration with the University of Miamis Miller School of Medicine through research agreements provides another strategic edge for ECP Pharma.

The ECP Pharma clinical trials team is currently in discussions with regulatory agencies in North and South America to be able to undergo multiple comprehensive, inclusive trials in addition to Phase 1 and 2 clinical trials set to begin in Miami, Florida. Several new FDA approved diagnostic technologies that the company is utilizing will allow it to quantify the improvement in each patients condition after the treatment course has been administered.

ECP Pharmas unique product pipeline uses a combination of cannabinoids, psychedelics and other compounds to therapeutically treat disease indications from which millions of patients suffer worldwide. Founded in March 2019, ECP Pharma is a global company with operations in the United States, Canada, and Latin America that is committed to research, development & manufacturing of innovative drug products that enhance human life. For more information about ECP Pharma and its work across multiple clinical and functional areas go to http://www.ecppharma.com.

About ECP Pharma Inc.

ECP Pharma Inc. is a clinical-stage pharmaceutical company focused on treating neurological and CNS diseases. The Company's product pipeline includes drugs derived from cannabinoids, psychedelic and other compounds to offer potential therapeutic benefit to multiple central nervous system diseases such as spasticity for Multiple Sclerosis, mild cognitive impairment for early on set of Alzheimers Disease and mild Traumatic Brain Injury (mTBI). More information may be found on the company's website http://www.ecppharma.com.

Original post:
ECP Pharma's Path Forward Clearer After FDA's Response To Pre-IND Submission On Its Neurological, CNS Diseases Drug Products - Business Wire

What is a neurologist? What they treat, procedures, and more

Posted on February 3, 2023 by Danzig

Neurologists are medical professionals who specialize in diagnosing and treating conditions that affect the nervous system.

A general practice doctor might make a referral to a neurologist if they believe that an individual shows signs of a neurological problem.

Neurological issues encompass a broad range of conditions, including Alzheimers disease, diabetic neuropathy, headaches, and nerve damage.

This article discusses the role of a neurologist, including the types of conditions they treat, the procedures they perform, and when a person might visit this specialist.

A neurologist is a medical doctor who specializes in evaluating, diagnosing, and treating diseases that affect the nervous system.

The nervous system has two parts:

Due to the complex nature of the nervous system, many neurologists focus on treating certain populations of people or people with specific neurological diseases.

After completing 4 years of medical school to become a physician, neurologists must complete a 4-year residency that consists of 1 year of general internal medicine or pediatrics training, followed by 3 years of neurology training. Some neurologists complete further subspecialty training, which is usually 13 years.

Examples of subspecialties within the field of neurology include:

Neurologists treat neurological conditions, which are problems that affect the brain, spinal cord, and nerves. These conditions include:

Sometimes neurologists evaluate people in the hospital who have had surgery or a medical problem if they have a new problem, such as a seizure or decreased alertness.

These neurological evaluations may help determine outlook or the likelihood of improving from a severe illness.

Neurologists can diagnose a range of conditions affecting the nervous system, such as:

Neurologists perform a range of different tests and procedures to diagnose and treat neurological conditions.

Some of these procedures include:

A neurologist can use a lumbar puncture to collect a sample of spinal fluid. They may use this procedure to help diagnose the following conditions:

Neurologists can also use a lumbar puncture to treat conditions that affect the spinal cord. They can inject anesthetics, antibiotics, or cancer treatments using a lumbar puncture needle.

A neurologist can use electromyography (EMG) to assess how well a persons muscles respond to electrical stimulation from motor neurons, which are nerves that control muscle movement.

Usually, a neurologist will also perform a nerve conduction study (NCV) to measure nerve activity by assessing someones response to superficial electric stimulation.

During an EMG, a specially trained technician inserts small needles called electrodes into the muscle. These electrodes record the different electrical activity that occurs in muscle tissue during periods of movement and rest.

The EMG machine produces an electromyogram, which is a record of this activity.

Neurologists can use the results of an EMG to diagnose neuromuscular diseases, such as myasthenia gravis and ALS.

Neurologists use electroencephalograms (EEG) to measure and record electrical activity in the brain.

Neurons in the brain communicate with other neurons through electrical impulses, which an EEG can detect. An EEG can also track brain wave patterns.

During an EEG, a technician will place electrodes on the persons head. These electrodes connect to a computer that converts electrical signals into patterns that the technician can view on a screen or print on a piece of paper.

Neurologists can use EEG results to identify abnormal electrical activity in the brain and diagnose certain conditions, such as:

Myasthenia gravis is a rare neuromuscular disease that weakens the muscles in the arms and legs. A neurologist can use a Tensilon test to diagnose myasthenia gravis.

Tensilon is the brand name of a drug called edrophonium, which prevents the breakdown of acetylcholine, a neurotransmitter that stimulates muscle movement.

Myasthenia gravis causes the immune system to attack acetylcholine receptors in the muscles, which causes muscle fatigue and decreased muscle movement.

During a Tensilon test, a neurologist will inject a small amount of Tensilon into the bloodstream. Then, they will ask the person to perform different movements to determine if muscle strength improves.

The neurologist will continue administering doses of Tensilon each time the person feels tired. If the person notices that their strength returns after each Tensilon injection, this indicates that they are likely to have myasthenia gravis.

A neurologist can use the following tests to help diagnose neurological disorders:

A neurological examination will involve tests to check muscle strength, memory, eye health and vision, and coordination. The tests are not usually painful but may cause some mild discomfort.

People will not need to prepare anything for their first neurological visit. The appointment may involve the neurologist:

After this initial examination, a neurologist may then perform several assessments, such as:

A doctor might refer someone to a neurologist if they have symptoms that indicate a neurological condition, such as:

Both neurologists and neurosurgeons treat people who have conditions that affect the nervous system. However, neurosurgeons perform surgery, whereas neurologists do not.

Neurosurgeons complete medical school and then neurosurgery residency, which includes 1 year of general surgery internship, followed by 68 years of neurosurgery residency.

All neurosurgeons are qualified to operate on the brain and the spine, and some neurosurgeons further specialize in highly technical procedures.

Generally, a persons general practice doctor will refer them to a neurologist or a neurosurgeon. Sometimes a neurologist may refer to a neurosurgeon if surgery would be beneficial, and sometimes a neurosurgeon will refer to a neurologist if the individual requires neurological management.

Neurologists diagnose and treat medical conditions that affect the nervous system.

A general practice doctor may refer a person to a neurologist if they show signs of a neurological disorder, such as:

Neurologists can perform various procedures to help diagnose and treat neurological conditions. However, if a person requires surgery, their neurologist or doctor will refer them to a neurosurgeon.

Clinical Care Effects of Risdiplam’s Expanded Indication in SMA – Neurology Live

Posted on June 9, 2022 by Danzig

In late May, the FDA granted an expanded indication approval to Genentech for risdiplam (Evrysdi) to now include the treatment of presymptomatic babies under 2 months old with spinal muscular atrophy (SMA). This decision makes the survival motor neuron splicing modifier the first approved treatment administered at home for this patient group. Risdiplam is now approved to treat SMA in both children and adults of all ages.1

The decision to expand risdiplams indication was based on interim efficacy and safety data from the RAINBOWFISH study (NCT03779334), which showed that, following 12 months of treatment with risdiplam, a majority of presymptomatic babies met key milestones of healthy babies. This included sitting, standing, and walking, in addition to maintaining the ability to swallow.2 The application was also supported by data from the open-label extension FIREFISH study (NCT02913482). In a cohort of 58 infants aged 1 to 7 months, 91% were alive after 3 years of treatment with risdiplam. Among the 48 infants who had an available motor assessment, 32 infants maintained and 4 gained the ability to sit without support for at least 5 seconds since month 24, as assessed by the Gross Motor Scale of the Bayley Scores of Infant and Toddler Development.3

To find out more about the implications of this new indication, NeurologyLive reached out to Richard Finkel, MD, RAINBOWFISHs principal investigator and the director of the Experimental Neuroscience Program at St. Jude Childrens Research Hospital. He shared his perspective on the data and decision in brief.

Richard Finkel, MD: This expansion of the label for risdiplam now provides a third option for parents and physicians to consider in treating babies with SMA under 2 months of age. It has a very favorable safety profile and early efficacy results from the RAINBOWFISH study, which led to this expanded label, suggests that it works really well, similar to nusinersen and onasemnogene abeparvovec.

The ease of administrationa daily oral drug that can be administered at homewill reduce the burden on many families that do not live near a major medical center or SMA clinic. Also, no screening or on-treatment lab are required or recommended, so no blood sticks to these little babies where drawing blood is often a challenge.

In the US, more than 95% of babies are now screened at birth for SMA. Getting risdiplam for a patient identified by newborn screening should be very easy once the payers adjust their coverage policies to reflect the change in the label. It is the only drug among the 3 that can be administered in the outpatient clinic and home setting. The other 2 drugs also work very well but require hospital-based outpatient care.

Transcript edited for clarity.

View post:
Clinical Care Effects of Risdiplam's Expanded Indication in SMA - Neurology Live

Scots with neurological conditions struggling to access appointments, study finds – STV News

Posted on June 9, 2022 by Danzig

Almost half of adults in Scotland with a neurological condition have experienced delays to access a routine appointment, according to a new study.

Research by the Neurological Alliance of Scotland also found that more than a third of adults (37%) waited more than a year for a diagnosis.

Meanwhile, nearly all children and young people (95%) and a majority of adults (80%) said that their neurological condition negatively impacts on their mental health.

The study also indicated that four in ten adults (40%) said that their mental health needs were not being met at all, whilst 55% of adults said they havent been asked about their mental wellbeing in the last three years.

And only 36% of adults and 26% of children and young people told the study that they completely understood the explanation of their condition given at diagnosis.

In its findings, the report highlights the profound impact of the coronavirus pandemic, whilst warning of a disproportionate impact of the cost-of-living crisis on those with neurological conditions.

The document also outlines that there is currently only one ME specialist nurse available in the whole of Scotland.

Alice Struthers, Neurological Alliance of Scotland programme director, said that it is alarming that most people with a neurological condition are unable to access the mental wellbeing support they need.

And she insisted that action must be taken to deliver care seamlessly between different parts of the health system in Scotland.

One in six people live with a neurological condition, but we do not have the workforce or services in place to provide the support they need, she said.

Delays to treatment and care can change your life forever, and it is of huge concern that people living with a neurological condition in Scotland have experienced such lengthy delays for routine appointments.

And it is alarming that most people with a neurological condition are unable to access the mental wellbeing support they need.

Finding out that you have a neurological condition is scary and confusing, and receiving the right information and support can make a real difference.

Action must be taken in Scotland to deliver care seamlessly between different parts of the health system, address the mental health crisis, and better understand the prevalence of neurological conditions so that we can create real and positive change for hundreds of thousands of people in Scotland.

A Scottish Government spokesperson said that long waiting lists are not acceptable and offered their sympathies to those patients waiting for treatment.

We are determined to improve the provision of neurological care, which is why we funded this important Patient Experience Survey from the Neurological Alliance Scotland. It is vital that people with neurological conditions feel enabled and involved in their care, they said.

Understanding the perspectives of those who access health care in Scotland will enable us to work together to identify good practice and drive up standards.

Long waiting lists are not acceptable, and we offer our sympathies to all patients waiting for treatment. We are working closely with NHS Boards to get those waiting for treatment the care they need as quickly as possible. Throughout the pandemic, NHS Boards have ensured that urgent services have continued as usual.

We are encouraged to see decreases in long waits for psychological therapies in Scotland, despite an increase in demand.

We provided an additional 9m to NHS boards to address waiting lists for PT and NHS staff have worked hard to address the backlogs.

Since 2007 psychology services staffing has doubled and we continue to support the creation of new posts.

We will continue to support all boards to clear mental health backlogs and meet the waiting times standard by March 2023.

We are currently refreshing our mental health strategy and are engaging with a range of organisations to help inform our approach. This will include engaging with Neurological Alliance of Scotland and Neuropsychological leads.

Scottish Conservative mental wellbeing spokesperson Sue Webber insisted that those with neurological conditions should not have to suffer in silence and must be seen quickly.

This survey paints an alarming picture for those with neurological conditions in Scotland and their ability to access mental health treatment system under the SNP, she said.

The vast majority of people living with neurological conditions say that their illness is impacting their mental health, yet these one million Scots are being badly let down.

People with neurological conditions, such as cerebral palsy, stroke, dementia and epilepsy, should not have to suffer in silence, and must be seen quickly.

The SNP must stop ignoring the needs of this significant group of the population and urgently act to ensure everyone in Scotland can easily and quickly access support for both their mental and physical health.

Growing up in Aberdeen, Mia was fit, happy and healthy.

She was on the Scottish Rhythmic Gymnastics Squad and competed around the UK, winning several medals.

At the age of 12, however, her life was turned upside down after being diagnosed with ME (myalgic encephalomyelitis), commonly known as chronic fatigue syndrome.

Mia would watch as her friends went on to college or jobs, whilst being unable to do so herself.

Now 18, Mia explains she has been left feeling totally lost and devastated following several visits to doctors and hospitals.

Over the last six years I have missed out on schooling, had to give up my gymnastics, and have missed out on most things that teenage girls do, she said.

Ive learned to try and manage according to what my body allows me to do.

Throughout the years, we have found that there is no help or understanding for people suffering with ME.

I have had several visits to doctors and hospitals and we have been left feeling totally lost and devastated. There has never been any empathy or help.

We have had to try find alternative treatments and pay for them ourselves with just a little bit of hope each time that at that point it would ease my symptoms and pain even if just for a little while.

Having previously worked in retail, Shannon was diagnosed with relapsing-remitting MS in January this year.

She was hospitalised for three weeks and had little to no function of her left leg, as well as weakness in her ankle and knee cap.

After being discharged from hospital at the start of February, she was told that she would receive physiotherapy at home once a week.

However, that didnt happen, with Shannon having to chase up the physiotherapy.

I still havent received any physio since being discharged on February 3, said Shannon.

I have done a lot at home myself to get me to a stage of being able to take small steps very wobbly without aids.

Im very determined to gain as much leg function back as I can and, if I have to do it myself due to the NHS letting me down, then thats what Ill do as I dont have much choice.

She added: My foot is still pretty weak and I walk with my foot at an angle rather than flat on the ground and Im unable to straighten my leg when walking.

I was without treatment for about eight weeks due to the pharmacist not delivering it, and I again had to chase this up.

Donald, who works for Glasgow City Council as a Gaelic development officer, has had cervical dystonia for nearly 40 years, affecting his neck and shoulders.

He attends regular appointments for botulinum toxin injections which helps to relax his muscles and straighten the twist in his form.

Every three months, he also attends the National Hospital of Neurology and Neurosurgery in London for electromyographic guided injections.

However, he was unable to access GP and other services during the coronavirus pandemic and could not travel to London.

I didnt have access to the botulinum toxin injections that I used to have every three months because of restrictions on travel and hospital and GP services at that time, he said.

It meant that rather than getting my injections every 12 weeks I was waiting at least 26 weeks or more.

My head is twisted over to the side and my shoulder comes up, and the injection is supposed to alleviate that to an extent although it doesnt take it all away.

Donald explains that not having access to treatments made the difficulty of living with the Covid-19 pandemic even more difficult.

He said: Not being able to have these appointments meant I was in more pain and discomfort than I would normally have.

Before the pandemic I also saw a physio regularly, but I couldnt go there for treatment for the best part of a year.

The delays were quite considerable but thankfully things are beginning to open up more again.

Covid generally was a very isolating experience for most people. Mentally it was tough and not having access to treatments definitely made a hard situation even more difficult.

Previously working as a nanny, Tanya had hoped to start a new job at a nursery when she was diagnosed with Cauda Equina Syndrome in March 2020 after suffering from severe pain.

She had an operation on her back as one of her discs had moved and was crushing her spinal nerve.

Tanya still has issues around going to the bathroom and has to use crutches to get around as she can only walk short distances.

She said that her husband had to give up one of his jobs to help care for her, with their lives having been flipped upside down.

I have not seen my surgeon since my operation because of Covid-19. I struggled to get them to refer me to a Neuropsychologist as I was home and struggling badly with the way I now was, Tanya explained.

I did eventually get one but was by phone only because of Covid, along with physio. I got one closer to home who was my lifesaver as she then told me about all the help that was out there for me and reached out to so many of her colleagues to help me. This was about six months after my condition.

My husband had to give up one of his jobs to help care for me as our whole lives had been flipped upside down and I needed help with everything personally and around the house.

I use crutches around my house and Im in a wheelchair outside as I can only walk a short distance and had to have a lot of adaptions around the house.

More here:
Scots with neurological conditions struggling to access appointments, study finds - STV News

Neurology specialist addresses aphasia, the illness affecting Bruce Willis – University of Miami: News@theU

Posted on April 1, 2022 by Danzig

Dr. James Galvin, chief of the Division of Cognitive Neurology at the University of Miami Miller School of Medicine, explains the brain disorder afflicting Bruce Willis that has caused him to step away from his acting career.

The entertainment world was shocked Wednesday when Bruce Willis and his ex-wife Demi Moore announced that the Hollywood icon of the Die Hard movie franchise is suffering from aphasia.

Around the world, many people Googled the word to learn what it meant and what the diagnosis would entail for the popular actor moving forward. In a statement on her Instagram account, Moore addressed Willis amazing fans to share that his cognitive abilities have been impacted.

As a result of this and with much consideration, Bruce is stepping away from the career that has meant so much to him, Moore said. This is a really challenging time for our family, and we are so appreciative of your continued love, compassion, and support. The post is signed by Willis current wife Emma, Moore, and his children Rumer, Scout, Tallulah, Mabel, and Evelyn.

Willis, 67, is a Hollywood superstar who has starred in dozens of critically acclaimed films including, Pulp Fiction, The Sixth Sense, and the Die Hard series. According to The New York Times, Willis has received three Golden Globe nominations, capturing one. He also won an Emmy for outstanding lead actor in a drama series for the TV show Moonlighting.

Dr. James Galvin, a professor of neurology at the University of Miami Miller School of Medicine and chief of the Division of Cognitive Neurology, explains aphasia and its treatment.

What is aphasia?

Aphasia is a medical term to describe conditions of disturbance of language (speaking, writing, reading, and comprehension) and is due to damage to the language centers in the brain. Aphasia can be fluent with good production of words, but a loss of the comprehension and understanding of the meaning of the words produced, or non-fluent with relatively preserved comprehension but a great difficulty in language expression such as speaking or writing. The illness can be caused by a focal injury such as a stroke, traumatic injury, or brain infection (encephalitis). In this case, the presentation of aphasia is typically mire acute or sudden. Aphasia can also be caused by more slowly progressing processes such as a brain tumor or a neurodegenerative disease such as Alzheimers disease or frontotemporal degeneration. In particular, a type of frontotemporal degeneration is known as primary progressive aphasia where language problems are the first, and in many cases the only symptoms.

Who is most at risk of contracting this disease?

This depends somewhat on the underlying cause. In the case of a neurodegenerative disease, older age is a strong risk factor. Frontotemporal degeneration, for example, typically begins sometime between the late 40s to mid-60s, while Alzheimers disease more commonly begins at a later age.Tumors and strokes can occur at any age but are more common with increasing age.

Is there a treatment for aphasia? Or, if someone is diagnosed with it, how can they manage the ailment?

This again depends somewhat on the underlying cause. If an underlying cause can be identified, such as a tumor or infection, treatment of the cause may improve symptoms. If due to a stroke or traumatic injury where the lesion is static or non-progressive, speech and language therapy can provide improvements or, at the very least, coping strategies. In the case of neurodegenerative disease, there are few clearly effective options, although some individuals may benefit for a short time from speech therapy. As swallowing difficulties can sometimes accompany language difficulties, it is important to rule this out so to avoid aspiration pneumonia.

What is the difference between simple forgetfulness and symptoms that indicate there is something more serious happeninglike aphasia, dementia, or Alzheimers?

Memory loss is not a part of the normal aging process, although many older adults subjectively report their memory is not as good as it once was. Instead of being truly forgetful, processing speed declines so that it takes longer than usual to recall information. But with time, the information is recalled, and people can benefit from clues or prompts. Progressive changes in memory, language, or other cognitive functions are often a sign of a neurodegenerative disease such as Alzheimers disease or a related dementia such as primary progressive aphasia, frontotemporal degeneration, or Lewy body dementia. Difficulty finding the right words can be an early sign of all of these conditions.

What is the difference between aphasia and dysphasia?

Aphasia is the loss of language, while dysphasia means impaired language. Neurologists often dont use the term dysphasia because it can be confused with dysphagia which means difficulty swallowing.

More here:
Neurology specialist addresses aphasia, the illness affecting Bruce Willis - University of Miami: News@theU

Race of people given Alzheimer’s blood tests may affect interpretation of results – EurekAlert

Posted on April 27, 2022 by Danzig

Three experimental blood tests used to identify people in early stages of Alzheimers disease perform differently in Black individuals compared to white individuals, according to a new study from Washington University School of Medicine in St. Louis.

The study showed that a fourth blood test the PrecivityAD test, which is commercially available in the U.S. and Europe through C2N Diagnostics was equally effective at detecting early Alzheimers disease regardless of the race of the person being tested. Since cutoffs between normal and abnormal test scores usually are set based on predominantly white volunteers, tests that perform differently in Black compared to white populations put Black patients at disproportionate risk of misdiagnosis and receiving inappropriate medical care.

The study is published April 21 in the journal Neurology.

Most people are diagnosed with Alzheimers only after they become forgetful and confused. Such cognitive symptoms arise relatively late in the course of the disease, a decade or more after the brain first begins to change. Scientists are working to identify people earlier using blood tests that detect Alzheimers-associated proteins in the blood, also known as biomarkers. But the field of Alzheimers biomarker research is based on data collected from groups of mostly white participants, raising concerns about whether tests based on such biomarkers are equally valid in diverse populations.

When you use a limited study population as, unfortunately, scientists have traditionally done in Alzheimers research and then try to apply the results to everyone, including people of diverse backgrounds, you could exacerbate health inequities, said lead authorSuzanne Schindler, MD, PhD, an associate professor of neurology. My hope is that this paper will help illustrate the need to increase the diversity of participants in Alzheimers studies. My colleagues and I are working to develop a much larger, multicenter study to better evaluate racial differences in Alzheimers-related blood biomarkers. This is a major priority for us.

The study was not designed to find the reason some Alzheimers biomarkers lead to different results in Black individuals compared to white individuals, but the presence of other health conditions could play a role. In this study, Black participants were more likely than white participants to have high blood pressure (67% versus 45%) and diabetes (28% versus 5%). Both conditions are linked to Alzheimers disease and may influence performance of biomarker tests, the researchers said.

The PrecivityAD test uses high-resolution mass spectrometry to measure the ratio of the Alzheimers proteins amyloid beta 42 and amyloid beta 40, as well as apolipoprotein E (APOE), a protein that affects risk for Alzheimers disease. The underlying technology behind the PrecivityAD test was developed at Washington University in the laboratory ofRandall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology and a co-author on this paper. C2N, the maker of the PrecivityAD test, is a Washington University startup and is based in St. Louis.

The researchers analyzed the accuracy of the PrecivityAD test and blood tests for two other proteins neurofilament light protein and two forms of the protein tau in 76 pairs of Black and non-Hispanic white participants. The pairs were created by pulling from a pool of volunteers who take part in research studies through Washington Universitys Charles F. and JoanneKnight Alzheimer Disease Research Center(Knight ADRC), and were matched on age, gender, cognitive status and presence of the high-risk genetic variant ofAPOE.More than 90% of individuals had no cognitive impairment.

The researchers determined whether each individual had the brain changes of Alzheimers disease using brain scans, analyzing the cerebrospinal fluid that surrounds the brain and spinal cord, or both. High levels of amyloid plaques found on brain scans or specific changes in the cerebrospinal fluid are both considered gold-standard evidence of Alzheimers.

Only the PrecivityAD test accurately classified people by Alzheimers status regardless of self-identified race. The other three blood tests were not as accurate at classifying people by Alzheimers status. Worse, they also performed differently in Black individuals compared to white individuals.

The fact these risk models have not been tested in a lot of populations makes me wary, because Alzheimers is a global disease, said co-author Thomas K. Karikari, PhD, an assistant professor in the Department of Psychiatry and Neurochemistry at the University of Gothenburg in Gothenburg, Sweden. Karikari is originally from Ghana. For example,APOEis a very good predictor of Alzheimers disease in people of European ancestry, but for people of non-European ancestry, it may not be a good predictor. We have to study these risk models in a wide variety of people to understand where does it work, where does it not work, and what are the factors that affect the performance of these models.

Race norming, or calibrating tests separately for each race, is not a satisfactory solution to the problem of differences in biomarkers across racial groups, Schindler and Karikari said. Such a practice can create or worsen racial disparities. For example, until 2021 the NFL routinely used race-normed cognitive tests to evaluate former players for cognitive impairments linked to injuries sustained on the field. Such tests consistently underestimated the degree of impairment suffered by Black players, making it difficult for them to obtain appropriate compensation. Washington University physicians do not use race-norming when assessing cognitive function, saidJohn C. Morris, MD, the Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology. Morris is the director of the Knight ADRC and a co-author on the paper.

Rather than trying to adjust for race in some way, it would be better to use tests that perform equally well in all individuals, Schindler said. Alternatively, we can try to understand the underlying factors that create these apparent racial differences and adjust for those underlying factors rather than race. What we dont want to do is to use these tests without evaluating their performance in diverse groups, because then we would fail in our duty to provide the best possible care to all.

Experimental study

People

Effect of race on prediction of brain amyloidosis by plasma A42/A40, phosphorylated tau, and neurofilament light.

21-Apr-2022

S.E. Schindler has received data on behalf of Washington University from C2N Diagnostics at no cost; T.K. Karikari reports no disclosures relevant to the manuscript; N.J. Ashton reports no disclosures relevant to the manuscript; R.L. Henson reports no disclosures relevant to the manuscript; K.E. Yarasheski is an employee of C2N Diagnostics, which offers the PrecivityADTM test described in this paper; T. West is an employee of C2N Diagnostics, which offers the PrecivityADTM test described in this paper; M.R. Meyer is an employee of C2N Diagnostics, which offers the PrecivityADTM test described in this paper; K.M. Kirmess is an employee of C2N Diagnostics, which offers the PrecivityADTM test described in this paper; Y. Li reports no disclosures relevant to the manuscript; B. Saef reports no disclosures relevant to the manuscript; K.L. Moulder reports no disclosures relevant to the manuscript; D. Bradford reports no disclosures relevant to the manuscript; A.M. Fagan has received research funding from Biogen, Centene, Fujirebio and Roche Diagnostics. She is a member of the scientific advisory boards for Roche Diagnostics, Genentech and Diadem. She consults for DiamiR and Seimens Healthcare Diagnostics Inc.; B.A. Gordon reports no disclosures relevant to the manuscript; T.L.S. Benzinger has investigator-initiated research funding from the NIH, the Alzheimers Association, the Barnes-Jewish Hospital Foundation and Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly). She participates as a site investigator in clinical trials sponsored by Avid Radiopharmaceuticals, Eli Lilly, Biogen, Eisai, Jaansen, and Roche. She serves as an unpaid consultant to Eisai and Siemens. She is on the Speakers Bureau for Biogen; J. Balls-Berry is a member of the patient advisory board and receives financial support for Dartmouth University project Implementation of Uterine Fibroid Option Grid Patient Decision Aids Across Five Organizational Settings (UPFRONT; NCT03985449); R.J. Bateman co-founded C2N Diagnostics. Washington University and Dr. Bateman have equity ownership interest in C2N Diagnostics and receive royalty income based on technology (stable isotope labeling kinetics and blood plasma assay) licensed by Washington University to C2N Diagnostics. He receives income from C2N Diagnostics for serving on the scientific advisory board. Washington University, with Dr. Bateman as coinventor, have submitted the US provisional patent application Plasma Based Methods for Detecting CNS Amyloid Deposition. He consults for Roche, Genentech, AbbVie, Pfizer, Boehringer-Ingelheim, and Merck; C. Xiong consults for Diadem; H. Zetterberg has served at scientific advisory boards and/or as a consultant for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx and Red Abbey Labs, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program; K. Blennow has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program; J.C. Morris, MD is the Chair of the Research Strategy Council of the Cure Alzheimers Fund.

Originally posted here:
Race of people given Alzheimer's blood tests may affect interpretation of results - EurekAlert

Dubai neurologist saves eyesight of patient with timely diagnosis and treatment – Gulf News

Posted on June 9, 2022 by Danzig

Dubai: A 36-year-old Indian expatriate, who nearly lost his eyesight to a rare condition that affects one in a million each year, had his vision restored thanks to the quick thinking by a Dubai neurologist. Timely diagnosis of Tolosa Hunt Syndrome (THS) helped the neurologist at Medeor Hospital initiate action that cured the patient of the ailment in three days.

In early April 2022, Faiz Muhammad Yusuf, an expatriate working in a company in Dubai, was excited and gearing up for his long-awaited vacation. However, just a few days before his flight, Yusuf, hailing from Chennai, India, experienced a severe headache and fever. This was followed by loss of vision in his left eye.

In addition, Yusuf also developed double vision, drooping of the left eyelid and multiple cranial nerve palsy. Due to extreme pain, he was unable to eat or drink. Yusufs friends rushed him to the Emergency Section of Medeor Hospital, Dubai, on April 2. A consultant ophthalmologist, who examined him, realised the problem had a neurological root and referred him to Dr Anas Abdul Majeed, consultant neurologist at the hospital. Upon detailed examination of the patient, Dr Majeed stumbled upon a rare diagnosis.

Comprehensive screening confirms diagnosis

Dr Majeed told Gulf News: After clinical examination of the patient, I prescribed a brain MRI. This imaging showed a well-defined lesion behind his left eye, which opened up possibilities for different diagnosis. Dr Majeed ordered a lumbar puncture, through which the cerebrospinal fluid of the patient was drawn and examined to rule out grave conditions, including meningitis. Only after following these diagnostic tests, was I able to diagnose that Yusuf suffered from the rare THS based on the diagnostic criteria and detailed investigations.

What is Tolosa Hunt Syndrome?

According to the United States-based National Organisation for Rare Disorders, THS is a rare neurological disorder occurring in one in a million persons a year, impacting the ocular neural nerve, characterised by sharp, stabbing pain in usually one eye, severe headache, accompanied by double vision or loss of vision. If diagnosed in time, it is possible to reverse the condition.

Dr Majeed added: This condition is idiopathic and there are no reasons as to why it occurs. It is not a congenital or genetic disorder and once diagnosed can be treated with steroids for complete recovery. It is important that the patient undergoes a proper treatment protocol to prevent any chances of a relapse.

Quick medical intervention is the key

Dr Majeed swiftly started the medications, including steroids. Yusuf responded well to medications and started showing signs of recovery just two days after being admitted to ICU [Intensive Care Unit]. We administered him IV steroids for three days and he showed significant improvement, Dr Majeed said.

Vision restored

After spending around four days in hospital, Yusuf was discharged and within two days after that, he flew back to India to spend his vacation with his family.

Yusuf, who was grateful to Dr Majeed, thanked him for the timely intervention and for saving his eyesight. I am grateful to God. I am also thankful to Dr Majeed and his team. My pain was unbearable. I could not eat or drink anything. I was unable to see anything. By the time, I reached the hospital, the pain had increased and my health had deteriorated considerably. I could have lost my eyesight had the doctor not done a correct diagnosis and treated me. My family and I will remember him in our prayers for our lifetime.

Challenging case

Dr Majeed added: Yusuf was lucky that his condition was correctly diagnosed as THS is a rare and complicated disease. Timely treatment through vast therapeutic armamentarium and teamwork was crucial to the patients timely recovery. He is advised regular follow-up after recovery.

Visit link:
Dubai neurologist saves eyesight of patient with timely diagnosis and treatment - Gulf News

Preliminary Study: Drug May Be Safe in Those with Mild Cognitive Impairment, Mild Dementia – Newswise

Posted on April 1, 2022 by Danzig

EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, THURSDAY, MARCH 31, 2022

Newswise MINNEAPOLIS A small, preliminary study of an investigational new drug being studied for mild cognitive impairment and mild dementia associated with Alzheimers disease suggests it is safe and may be associated with improvements in executive function, thinking and memory skills. The study is released today, March 31, 2022, and will be presented at the American Academy of Neurologys 74th Annual Meeting being held in person in Seattle, April 2 to 7, 2022 and virtually, April 24 to 26, 2022. The drug, called SAGE-718, is also in clinical trials for the treatment of cognitive impairment associated with Parkinsons disease and Huntingtons disease.

Cognitive impairment is often one of the earliest signs of Alzheimers disease, can be very difficult for patients and their families, and represents an area of great unmet medical need, said study author Aaron Koenig, MD, of Sage Therapeutics in Cambridge, Mass., the maker of the investigational drug. These results support further research with larger numbers of people to determine whether this therapy is safe and effective in treating cognitive impairment in Alzheimers disease and related disorders and in improving how well people can function independently in their everyday lives.

The study involved 26 people with an average age of 67. They had an average score of 20.7 points on a common cognitive test, indicating cognitive performance consistent with mild cognitive impairment or mild dementia. The participants took SAGE-718 daily for two weeks and were then followed for another two weeks. They completed tests of thinking and memory at the beginning of the study, at the end of treatment, and after one month. Both the participants and researchers knew that SAGE-718 was being administered.

The study was designed mainly to gather data on the drugs safety. There were no serious side effects of the drug. Five people had mild or moderate side effects believed to be related to the drug, such as headache or constipation.

After one month, the participants scores on the cognitive test had improved by an average of 2.3 points, to 22.8 points.

Koenig said some participants also had improvement in assessments of how well they were able to complete their daily activities, especially in complex activities such as using a computer, carrying out household chores, and managing their medications. This coincided with consistent improvement on multiple tests of executive functioning that were administered during the trial.

Koenig said, If replicated in future studies, such improvements suggest that this drug may eventually provide meaningful benefits to people in their everyday lives.

SAGE-718 is a type of drug called a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptors.

The studys limitations include its small size and that participants and researchers knew that the drug was being administered, which could lead to bias.

The study was supported by Sage Therapeutics, Inc.

Learn more about brain health at BrainandLife.org, home of the American Academy of Neurologys free patient and caregiver magazine focused on the intersection of neurologic disease and brain health. Follow Brain & Life on Facebook, Twitter and Instagram.

When posting to social media channels about this research, we encourage you to use the American Academy of Neurologys Annual Meeting hashtag #AANAM.

The American Academy of Neurology is the worlds largest association of neurologists and neuroscience professionals, with over 38,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimers disease, stroke, migraine, multiple sclerosis, concussion, Parkinsons disease and epilepsy.

For more information about the American Academy of Neurology, visit AAN.com or find us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

More here:
Preliminary Study: Drug May Be Safe in Those with Mild Cognitive Impairment, Mild Dementia - Newswise

Doctors say heavy Tik-Tok usage is causing neurological health complications – WPMT FOX 43

Posted on April 1, 2022 by Danzig

The medical professionals say these teens are developing tics after watching videos of those with Tourette's Syndrome.

HARRISBURG, Pa. With its popularity growing since its launch in the U.S. in 2018, Tik-Tok has become a sensation for its users promoting creativity and entertainment.

Doctors across the globe say they are seeing complications in movement from teenage girls as a greater number are seeking treatment for tics. They say the young teens are developing the tics after watching Tik-Tok videos of creators who have Tourette's syndrome.

One might ask, what is the difference?

"A tic is a complicated movement that's stored in the center part of the brain that you feel this pressure that pushes movement out and you can try to hold it back but it gets stronger and stronger often when you do until it forces it's way out," said Dr. Jeremy Timothy, a pediatric neurologist for WellSpan Health.

Timothy says Tourette's syndrome, on the other hand, is a type of tic disorder, where people have multiple tics persistently over a course of time. This type of disorder usually arises in children, but Timothy says he's seen cases in teens now.

Research has pointed out teen girls who developed these tics during the pandemic had pre-existing mental health issues making them prone to other disorders.

Dr. Melissa Brown, a psychologist for UPMC, says stress and anxiety toppled by the pandemic are a "perfect storm" to create issues like these.

"The pandemic hit, placing a lot of social constraints on our teens, and girls tend to be very social and integrated into their social circles," she said.

Timothy says it's important for parents to speak to their children's doctors and if they happened to have tics, seek out treatments. Some of these include medications or CBIT -- Comprehensive Behavioral Intervention for Tics.

This is a therapy where one learns tricks to substitute different movements for tics that is less noticeable or shift gears in your mind from something that may trigger tics.

Another way for parents to help is to be more engaged and present in their child's life.

"Engaging in conversations, getting more physical activity, making sure they're sleeping well-our teens do need a lot of sleep," said Brown. "Of course, watch their diets and checking out what they're consuming."

Tik-Tok has responded to the issue publically, stating people with Tourette's Syndrome use the app "to express themselves authentically, find community and fight stigma."

More:
Doctors say heavy Tik-Tok usage is causing neurological health complications - WPMT FOX 43

Innovative therapy reverses neuropathology in elderly woman | Duke Department of Neurology – Duke Department of Neurology

Posted on April 1, 2022 by Danzig

A female in her 70s experienced weakness in her legs, trouble swallowing, and several falls. When she fell and couldnt get up, she called an ambulance and was transported to a local hospital.

Physicians at the hospital consulted Duke Healths neurology experts, who suggested a diagnosis of Guillain-Barre syndrome. The local hospital initiated a standard treatment for Guillain Barreintravenous immunoglobulin (IVIG)but the patient did not respond after two treatments. Because of a rapid deterioration of muscular function, she was transferred to Duke Hospital overnight. The deterioration ascended from her feet and began to compromise her pharyngeal and respiratory muscles.

When I arrived at the hospital, she was decompensating quickly. She was taken to the neurological ICU where she was intubated and placed on a ventilator, says Jordan L. Mayberry, MD, a neuromuscular specialist on duty that day. Mayberry was concerned by her lack of response to IVIG. To head off any further deterioration, he made the fast decision to change to a treatment the local hospital did not offer.

What therapy offered at Duke but few other North Carolina hospitals did Mayberry institute for a better chance at speeding the patients recovery?

Select Page ::